Line 230: | Line 230: | ||
<a href="https://2017.igem.org/Team:Tuebingen/Inspiration"style="margin-right:1.5em;">Inspiration</a> | <a href="https://2017.igem.org/Team:Tuebingen/Inspiration"style="margin-right:1.5em;">Inspiration</a> | ||
<a href="https://2017.igem.org/Team:Tuebingen/Demonstrate"style="margin-right:1.5em;">Results</a> | <a href="https://2017.igem.org/Team:Tuebingen/Demonstrate"style="margin-right:1.5em;">Results</a> | ||
− | <a href="https://2017.igem.org/Team:Tuebingen/HP | + | <a href="https://2017.igem.org/Team:Tuebingen/HP"style="margin-right:1.5em;">Human Practice</a> |
<a href="https://2017.igem.org/Team:Tuebingen/Lab"style="margin-right:1.5em;">Lab</a> | <a href="https://2017.igem.org/Team:Tuebingen/Lab"style="margin-right:1.5em;">Lab</a> | ||
<a href="https://2017.igem.org/Team:Tuebingen/Attributions"style="margin-right:1.5em;">Attributions</a> | <a href="https://2017.igem.org/Team:Tuebingen/Attributions"style="margin-right:1.5em;">Attributions</a> |
Revision as of 03:09, 2 November 2017
composite parts
Composite Parts
We designed different composite parts which are charaterized on the registry pages.
L-rhamnose dependent expression of SHV-1, an extended spectrum β-lactamase
pRha promoter with downstream RBS which allows L-rhamnose dependent expression of downstream clones coding sequences
L-rhamnose dependent expression of β-lactam synthetase